Articles tagged "Biopsy"

2021 American Transplant Congress
Treatment and Outcomes of Kidney Transplant Recipients with C4d Negative Antibody Mediated Rejection
M. Walsh, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study is to describe and evaluate treatment practices and patient outcomes for kidney transplant recipients with presence of C4d negative…
2021 American Transplant Congress
Sampling Renal Biopsies in Pre-Clinical Research for Comprehensive Assessment
C. M. Edwards¹, C. Albert², D. Stern¹, J. Langford¹, W. Day², J. R. DiRito¹, W. M. Saltzman², M. Kashgarian³, J. S. Pober⁴, G. T. Tietjen¹
¹Surgery, Yale School of Medicine, New Haven, CT, ²Biomedical Engineering, Yale School of Medicine, New Haven, CT, ³Pathology, Yale School of Medicine, New Haven, CT, ⁴Immunobiology, Yale School of Medicine, New Haven, CT
*Purpose: Previous literature has demonstrated that single biopsies are not representative of a whole kidney in clinical assessments. In this study we aimed to design…
2021 American Transplant Congress
Detection of Rejection in Kidney Transplant Patients Using an Algorithm That Combines Donor Fraction and Absolute Donor-derived Cell-free DNA
S. Bunnapradist¹, E. Ahmed², M. Maninder², Z. P. Demko², P. R. Billings², H. Tabriziani², P. Gauthier³
¹David Geffen Sch of Med @ UCLA, Los Angeles, CA, ²Natera, Inc., San Carlos, CA, ³Natera, Inc., Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the plasma of renal allograft patients is a clinically validated biomarker for allograft injury and rejection. Several dd-cfDNA assays…
2021 American Transplant Congress
Donor-derived Cell-free DNA in Upper Extremity Vascular Composite Allograft Recipients
R. Kalsi¹, M. Abuzeineh², J. Littleton¹, J. T. Shores¹, D. S. Cooney¹, C. Cooney¹, R. J. Redett¹, G. Brandacher¹, D. C. Brennan²
¹Plastic and Reconstructive Surgery, Johns Hopkins University, Baltimore, MD, ²Nephrology, Johns Hopkins University, Baltimore, MD
*Purpose: Diagnosing rejection in VCA recipients relies on clinical exam and biopsy which are both easily confounded by common causes of skin irritation. dd-cfDNA in…
2021 American Transplant Congress
PLA2R Status and Antibody Mediated Rejection in Kidney Transplant with Membranous Nephropathy
H. S. Han¹, A. Urisman², J. Shoji¹
¹Kidney Transplant Service, University of California, San Francisco, San Francisco, CA, ²Pathology, University of California, San Francisco, San Francisco, CA
*Purpose: Membranous nephropathy (MN) in transplanted kidney is categorized as de novo or recurrent disease. This immune complex glomerulopathy presents with varying levels of proteinuria,…
2021 American Transplant Congress
Gene Expression Profiles Assessed by the Nanostring nCounter® Platform May Differentiate Different Types of Rejection, and Importantly, T-Cell Mediated Rejection from BK Virus Nephropathy
K. R. Degner¹, K. J. Swanson¹, S. Parajuli¹, D. Mandelbrot¹, N. Garg¹, F. Aziz¹, M. Mohamed¹, W. Zhong¹, L. Ptak¹, N. A. Wilson¹, R. Woodward², A. Djamali¹
¹University of Wisconsin, Madison, WI, ²CareDx, Inc., San Francisco, CA
*Purpose: Allograft biopsies are considered the gold standard for diagnosis and therapeutic guidance in kidney transplant recipients. Expanding current biopsy assessments to include gene expression…
2021 American Transplant Congress
Intermediate Outcomes Following Early Inflammatory Changes on Surveillance Biopsies
I. Melgarejo¹, V. Viswanathan², A. Sharma¹, P. Sood¹, C. Puttarajappa¹, N. Shah¹, M. Molinari¹, A. Tevar¹, C. Wu¹, S. Hariharan¹, R. Mehta¹
¹Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Renal-electrolyte, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The implications on early inflammatory changes on surveillance biopsies on intermediate and long-term outcomes is unclear.*Methods: Of the 1000 kidney transplant (live donor and…
2021 American Transplant Congress
Characterisation of Distinct Graft Infiltrates Following Cellular Therapy in Kidney Transplant Recipients
M. O. Brook¹, P. N. Harden², I. Roberts², W. R. Mulley³, J. Hester¹, M. E. Reinders⁴, F. Issa¹
¹Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom, ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ³Department of Nephrology, Monash Medical Centre, Melbourne, Australia, ⁴Division of Nephrology and Transplant Center, Leiden University Medical Center, Leiden, Netherlands
*Purpose: Cellular therapy is an emerging treatment in the field of clinical transplantation with the potential to improve both short and long-term transplant outcomes. We…
2021 American Transplant Congress
Comparison of Donor-derived Cell Free Dna Between Recipients with First Solitary Allograft and Regrafts
S. Paluri¹, S. Muthusamy¹, M. Shinbashi¹, G. Gupta¹, B. Dale², Z. Kashi³, P. Halloran⁴, D. Kumar¹
¹Virginia Commonwealth University, Richmond, VA, ²CareDx, Brisbane, CA, ³Kashi Clinical Laboratories, Portland, OR, ⁴ATAGC, Edmonton, AB, Canada
*Purpose: Donor derived-cell free DNA (dd-cfDNA) is a biomarker of immunological injury. Multiple studies have validated its utility in recipients of first solitary kidney transplants…
2021 American Transplant Congress
Given the Potential Impact on Liver Transplant Selection, Revisiting the Current Standard of Diagnosis of Hepatocellular Carcinoma
K. Amarell, B. Fisher, B. Park, K. Ko, B. Kallakury
Department of Pathology & Laboratory Medicine, Georgetown University School of Medicine, Washington, DC
*Purpose: The current standard of diagnosis of hepatocellular carcinoma (HCC) relies on non-invasive radiographic methods, namely computerized tomography (CT) and/or magnetic resonance imaging (MRI). However,…

« Previous Page
1
…
7
8
9
10
11
…
43
Next Page »